Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maravai Lifesciences Holdings Inc Cl A (MRVI)

Maravai Lifesciences Holdings Inc Cl A (MRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 920,545
  • Shares Outstanding, K 255,707
  • Annual Sales, $ 259,190 K
  • Annual Income, $ -144,850 K
  • EBIT $ -140 M
  • EBITDA $ 86 M
  • 60-Month Beta 0.33
  • Price/Sales 3.66
  • Price/Cash Flow 6.00
  • Price/Book 2.19

Options Overview Details

View History
  • Implied Volatility 183.65% (+20.53%)
  • Historical Volatility 71.95%
  • IV Percentile 85%
  • IV Rank 30.25%
  • IV High 503.25% on 04/08/25
  • IV Low 45.06% on 09/05/25
  • Expected Move (DTE 5) 1.15 (31.88%)
  • Put/Call Vol Ratio 11.11
  • Today's Volume 109
  • Volume Avg (30-Day) 726
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 21,343
  • Open Int (30-Day) 21,413
  • Expected Range 2.45 to 4.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.22 +11.80%
on 11/13/25
3.95 -8.86%
on 12/10/25
+0.35 (+10.77%)
since 11/12/25
3-Month
2.55 +41.45%
on 11/07/25
3.95 -8.86%
on 12/10/25
+0.93 (+34.83%)
since 09/12/25
52-Week
1.66 +116.22%
on 04/17/25
6.21 -42.03%
on 01/08/25
-2.06 (-36.40%)
since 12/12/24

Most Recent Stories

More News
Maravai LifeSciences Announces November 2025 Investor Conference Schedule

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference...

MRVI : 3.60 (-2.96%)
Maravai LifeSciences Reports Third Quarter 2025 Financial Results

Organizational restructuring and operating cost reduction initiatives on track

MRVI : 3.60 (-2.96%)
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 6, 2025

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2025 financial...

MRVI : 3.60 (-2.96%)
Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue...

MRVI : 3.60 (-2.96%)
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans...

MRVI : 3.60 (-2.96%)
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF has commenced an investigation into...

MRVI : 3.60 (-2.96%)
Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer

MRVI : 3.60 (-2.96%)
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

MRVI : 3.60 (-2.96%)
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

MRVI : 3.60 (-2.96%)
Maravai LifeSciencesReleases 2024 Sustainability Report

MRVI : 3.60 (-2.96%)

Business Summary

Maravai LifeSciences Holdings Inc. is a life sciences company providing products for the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company offer products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and...

See More

Key Turning Points

3rd Resistance Point 3.97
2nd Resistance Point 3.85
1st Resistance Point 3.73
Last Price 3.60
1st Support Level 3.49
2nd Support Level 3.37
3rd Support Level 3.25

See More

52-Week High 6.21
Fibonacci 61.8% 4.47
Fibonacci 50% 3.94
Last Price 3.60
Fibonacci 38.2% 3.40
52-Week Low 1.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar